Ruxolitinib protects lipopolysaccharide (LPS)-induced sepsis through inhibition of nitric oxide production in mice

BACKGROUND: Ruxolitinib is an inhibitor of Janus kinases (JAK) 1/2. It was authorised recently by the U.S. Food and Drug Administration (FDA) as a new Myelofibrosis treatment. In this study, we identified ruxolitinib as a new inhibitor of nitric oxide (NO) production in response to lipopolysaccharid...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Ann Transl Med
Autori principali: Li, Li, He, Xingfeng, Wang, Xingtong, Sun, Yu, Wu, Guosheng, Fang, He, Wang, Chen, Luo, Pengfei, Xia, Zhaofan
Natura: Artigo
Lingua:Inglês
Pubblicazione: AME Publishing Company 2020
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7214887/
https://ncbi.nlm.nih.gov/pubmed/32411769
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm-20-2972
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi